How many patents does
Innate Pharma have?
patents
621
families
81
granted
122
applications
499
US
132
EP
92
WO
74
JP
43
CN
36
KR
16
RoW
228
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Innate Pharma
Top ten assignees appearing on patents
2009 - 2018
| innate pharma | 529 |
| novo nordisk | 93 |
| bristol-myers squibb company | 12 |
| orega biotech | 5 |
| innat farma | 2 |
| innejt farma | 2 |
| laboratoires mayoly spindler | 1 |
| jac products | 1 |
| innate pharmaceuticals | 1 |
| inmate pharma | 1 |
2009
| innate pharma | 28 |
| novo nordisk | 6 |
| innat farma | 1 |
2018
| innate pharma | 62 |
| novo nordisk | 3 |
| bristol-myers squibb company | 2 |
| orega biotech | 2 |
Innate Pharma
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies | 44 | 2003 |
| monoclonal antibodies against nkg2a | 32 | 2004 |
| methods and compositions for increasing the efficiency of therapeutic antibodies using n… 🛈 | 30 | 2003 |
| antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use | 27 | 2003 |
| neutralization of inhibitory pathways in lymphocytes | 23 | 2014 |
| anti-kir antibodies for the treatment of inflammatory disorders | 22 | 2011 |
| tlr3 binding agents | 17 | 2009 |
| kir-binding agents and methods of use thereof | 16 | 2005 |
| therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterp… 🛈 | 16 | 2004 |
| nk cell modulating treatments and methods for treatment of hematological malignancies | 16 | 2010 |